Aprea Therapeutics, Inc. Lease Obligation Incurred
Aprea Therapeutics, Inc. (APRE) reported Lease Obligation Incurred of $123.79 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-26.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalLeaseObligationsIncurred · last filed 2024-03-26
- Aprea Therapeutics, Inc. lease obligation incurred for the quarter ending 2022-12-31 was $10.17K.
- Aprea Therapeutics, Inc. lease obligation incurred for the quarter ending 2022-09-30 was -$10.17K.
- Aprea Therapeutics, Inc. lease obligation incurred for the quarter ending 2022-06-30 was $0.00.
- Aprea Therapeutics, Inc. lease obligation incurred for the quarter ending 2022-03-31 was $123.79K.
- Aprea Therapeutics, Inc. lease obligation incurred for fiscal 2022 was $123.79K, a 0.21% decline from fiscal 2021.
- Aprea Therapeutics, Inc. lease obligation incurred for fiscal 2021 was $124.04K.
| Period end | Lease Obligation Incurred 3 month | Lease Obligation Incurred 6 month | Lease Obligation Incurred 9 month | Lease Obligation Incurred 12 month |
|---|---|---|---|---|
| 2022-12-31 | $10.17K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $0.00 derived: sum of 2 quarters · filed 2024-03-26 | $0.00 derived: sum of 3 quarters · filed 2024-03-26 | $123.79K 10-K · filed 2024-03-26 |
| 2022-09-30 | -$10.17K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$10.17K derived: sum of 2 quarters · filed 2023-11-09 | $113.61K 10-Q · filed 2023-11-09 | $113.61K derived: sum of 4 quarters · filed 2024-03-26 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $123.79K 10-Q · filed 2023-08-10 | $123.79K derived: sum of 3 quarters · filed 2024-03-26 | |
| 2022-03-31 | $123.79K 10-Q · filed 2023-05-15 | $123.79K derived: sum of 2 quarters · filed 2024-03-26 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $124.04K 10-K · filed 2024-03-26 | ||
| 2021-09-30 | $124.04K 10-Q · filed 2022-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |